Kodiak Sciences Inc

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kodiak Sciences reports strong clinical progress and eyes market expansion

Kodiak Sciences Inc showcased strong clinical progress with positive Phase III results and plans to advance all 3 programs into Phase III studies in 2024.
The company's focus on durability, diverse pipeline, and strategic approach position them well in addressing retinal vascular diseases.
While facing challenges in differentiation and long-term efficacy demonstration, Kodiak has opportunities to expand market reach through innovative study designs and patient subgroup exploration.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Axsome Therapeutics

There's a pair of gems hiding in plain sight.

2 Under-the-Radar Biotech Stocks That Could Make You Rich

Adverum Biotechnologies

REGENXBIO

Here's what to look out for at the American Academy of Ophthalmology's annual meeting later this week.

3 Blindness-Fighting Biotech Stocks That Could Surge This Week

BridgeBio Pharma Inc

These small-cap biotechs have fallen to bargain prices.

3 Top Biotech Stocks to Buy in October

ACADIA Pharma

Mesoblast

3 Biotech Stocks That Soared Last Week

As of late, it has definitely been a great time to be an investor in Kodiak Sciences Inc. (KOD).

Kodiak Sciences Inc. (KOD) Shares March Higher, Can It Continue?

News for Kodiak Sciences Inc Stock (KOD)